JP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Halozyme Therapeutics (NASDAQ:HALO) but lowers the price target from $53 to $52.
August 06, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Halozyme Therapeutics but lowers the price target from $53 to $52.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100